Hypercholesteremia
4
Pipeline Programs
6
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 4 programs with unclassified modality
Competitive Landscape
6 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programPattern of Statins Use in CataloniaN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Sharp TherapeuticsMK-0524A
AstraZenecaPattern of Statins Use in Catalonia
ConceptionLimicol
Clinical Trials (4)
Total enrollment: 181,645 patients across 4 trials
Lipitor Phase 4 Clinical Trial in Hypercholesteremia Patients With Yellow Coronary Plaque
50 patients
Phase 4Completed
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
Start: Jul 2006Est. completion: Jan 2007825 patients
Phase 3Completed
Pattern of Statins Use in Catalonia
Start: Feb 2012Est. completion: Feb 2012180,723 patients
N/ACompleted
Effects of Limicol on LDL-cholesterol
Start: Dec 2008Est. completion: May 201147 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.